Inclusion Criteria:

- histologically confirmed cutaneous melanoma stages IIB, IIC or III (AJCC)

- patients non-detectable disease (NED) after surgery as asserted by CAT scans.
Melanoma pts with unknown primary tumor site could be included in the study

- life expectancy > 6 months

- performance status (ECOG) 0 or 1

- Time post surgery not more than 4 months

- no chemotherapy, radiotherapy or any biological treatments prior to this study.

- patients must have CATscans of brain, thorax, abdomen and pelvis in the 60 previous
days to trial enrolling

- To have laboratory studies (no more than 15 days before entering the study)

- laboratory eligibility criteria include: hematocrit: ≥35 (hemoglobin > 10,5 gr %);
WBC count > 3500/mm3, platelets > 100.000/mm3, total and direct bilirubin, serum
oxalacetic transaminase and glutamic pyruvic transaminase < 1.5 fold the upper normal
value; LDH ≤ 450 mU/ml

- negative serology for HIV, anti-HCV and HBsAg

- serum creatinine < 2.0 mg %

- all patients must give written informed consent before inclusion in the Study.

Exclusion Criteria:

- Pregnant or breast-feeding women

- Diabetes (Type I or II)

- Antecedents of psychiatric diseases

- Evidence of active infections

- Antecedents of viral or autoimmune hepatitis

- Previous autoimmune diseases

- Morbid Obesity, defined as CMI (Corporal mass index)>37 kg/m2 in women and >40 kg/m2
in men.

- Other diseases that require treatment with regular corticoids or non steroids
anti-inflammatory drugs